FBXW7 and glaucoma: Consequently, it can be concluded that encapsulation of AGO inside bilosomal formulations improves the IOP reducing effect of AGO and enhanced its bioavailability and it is very promising for the treatment of glaucoma with a higher bioavailability and lower side effects.